Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Four CRISPR Companies Reach Agreement in Patent Case

XTALKS VITALS NEWS

DNA

These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique.

Share this!

December 20, 2016 | by Sarah Hand, M.Sc.

Four companies focusing on CRISPR gene editing have agreed to form an intellectual property (IP) alliance. CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics have all agreed to honor their respective licensing deals with the co-owners of the IP, including the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna.

“We are pleased that we have come to this global agreement with Intellia, Caribou, ERS and the co-owners and other licensees of this foundational CRISPR/Cas9 technology IP,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “We believe that the Charpentier-University of California-Vienna IP estate constitutes the foundational IP in the CRISPR/Cas9 editing space. Intellia, CRISPR Therapeutics, Caribou, and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing development of our product candidates, as well as those of our corresponding partners and licensees.”



These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique. The agreement ensures that all four companies respect each other’s global rights to the technology.

Jennifer Doudna and Emmanuelle Charpentier are credited with the co-discovery that the CRISPR-Cas9 system could be applied to gene editing in mammalian cells. Since then, the two have independently founded CRISPR-focused biotechs, with Doudna founding Caribou and Intellia, and Charpentier founding CRISPR and ERS.

“Through this agreement, we are ensuring alignment in our efforts to protect and prosecute the foundational CRISPR/Cas9 discoveries made by Dr. Doudna, Dr. Charpentier, and their teams, which have transformed the genomics field and unleashed new therapeutic possibilities,” said Nessan Bermingham, CEO and founder, Intellia Therapeutics. “This strengthens Intellia's IP position as we continue forging ahead with the discovery and development of therapies for patients worldwide.”


Keywords: CRISPR, Gene Editing, Intellectual Property


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Study Finds Hospital-Acquired Anemia Linked with Poorer Patient Outcomes

May 19, 2017 - New research conducted at UT Southwestern Medical Center has found that one in three patients admitted to hospital develop anemia as a result.

Featured In: Life Science News


Scott Gottlieb Takes the Helm of the FDA

May 18, 2017 - One of the first things on his regulatory agenda is to address drug pricing – a hot topic in the US pharmaceutical industry today.

Featured In: Pharmaceutical News


Opioid Prescriptions for Minor Injuries Contribute to Growing Epidemic

May 18, 2017 - While many assume that patients prescribed large quantities of opioid drugs – such as oxycodone – for chronic pain are at the highest risk of abuse and dependence, new research suggests that small prescriptions for these narcotic painkillers could be just as dangerous.

Featured In: Drug Safety News


LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations


Respiratory Endpoints, Scientific Leadership and the Asia-Pacific Region


Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges


Enabling Patient-Centric Digital Transformation in Pharma and Biotech


Copyright © 2016-2017 Honeycomb Worldwide Inc.